Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 11, Number 10—October 2005

Research

Methicillin-resistant Staphylococcus aureus and Vancomycin-resistant Enterococci Co-colonization1

Jon P. Furuno*Comments to Author , Eli N. Perencevich*†‡, Judith A. Johnson*†, Marc-Oliver Wright‡2, Jessina C. McGregor*, J. Glenn Morris*†, Sandra M. Strauss*, Mary-Claire Roghman*†, Lucia L. Nemoy*†, Harold C. Standiford‡, Joan N. Hebden‡, and Anthony D. Harris*†‡
Author affiliations: *University of Maryland School of Medicine, Baltimore, Maryland, USA; †Veterans' Affairs Maryland Health Care System, Baltimore, Maryland, USA; ‡University of Maryland Medical Center, Baltimore, Maryland, USA

Main Article

Table 1

Characteristics of the study population by co-colonization status*

Characteristic MRSA/VRE co-colonization (n = 65) No co-colonization (n = 2,375) p value
Demographic variable
Mean age, y (SD) 61.1 (15.1) 55.7 (16.0) <0.01
Male sex, n (%) 43 (66.2) 1,277 (53.8) 0.05
Variables from current admission
Type of ICU (MICU), n (%) 49 (75.4) 1,014 (42.7) <0.01
Transfer from another hospital, n (%) 10 (15.4) 711 (29.9) <0.01
Comorbidities
HIV/AIDS, n (%) 3 (4.6) 77 (3.2) 0.54
Malignancy, n (%) 6 (9.2) 423 (17.8) 0.07
Cardiac disease, n (%) 20 (30.8) 486 (20.5) 0.04
Diabetes mellitus, n (%) 14 (21.5) 486 (20.5) 0.83
Liver disease, n (%) 2 (3.1) 182 (7.7) 0.17
Renal disease, n (%) 3 (4.6) 74 (3.1) 0.50
Mean Charlson comorbidity score (SD) 2.1 (2.2) 2.3 (2.3) 0.37
Antimicrobial drugs before culture
Vancomycin, n (%) 14 (21.5) 226 (9.5) <0.01
Piperacillin-tazobactam, n (%) 17 (26.2) 398 (16.8) 0.05
Imipenem, n (%) 2 (3.1) 72 (3.0) 0.98
Cephalosporins, n (%) 7 (10.8) 426 (17.9) 0.14
Aminoglycosides, n (%) 4 (6.2) 109 (4.6) 0.55
Fluoroquinolones, n (%) 11 (16.9) 223 (9.4) 0.04
Variables from previous admissions
Previous MRSA colonization/infection 31 (47.7) 145 (6.1) <0.01
Previous VRE colonization/infection 18 (27.7) 178 (7.5) <0.01
Hospital admission (<1 y), n (%) 37 (57.9) 751 (31.6) <0.01
ICU admission (<1 y), n (%) 17 (26.2) 309 (13.0) <0.01
Antimicrobial drugs during admission (<1 y), n (%) 33 (50.8) 606 (25.5) <0.01

*MRSA, methicillin-resistant Staphylococcus aureus; VRE, vancomycin-resistant enterococci; SD, standard deviation; ICU, intensive care unit; MICU, medical ICU.

Main Article

1These data were presented in part at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, September 2004.

2Current affiliation: Marshfield Clinic Research Foundation, Marshfield, Wisconsin, USA.

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO